Posted by Michael Wonder on 13 Oct 2017
Highlights from the CHMP 9-12 October 2017 meeting
13 October 2017 - One generic medicine recommended for approval.
The EMA's CHMP has recommended one generic medicine for approval at its October meeting: Tacforius (tacrolimus), for prophylaxis and treatment of transplant rejection.
The Committee recommended extensions of indications for Alecensa, Bydureon, Cubicin, Faslodex, Pegasys and Zytiga.
